Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma

European Journal of Surgical Oncology

Volumn 37, Issue 6, 2011, Pages 513-520

  Chen, L ^a   Shi, Y ^a   Jiang, C Y ^a   Wei, L X ^a   Wang, Y L ^a   Dai, G H ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; pan Ras; pERK1 2; pMEK1; Prognosis; Raf 1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAF PROTEIN; RAS PROTEIN;

ADULT; ARTICLE; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MAP KINASE KINASE 1; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RAF KINASES; RAS PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79956051553     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.01.023     Document Type: Article

References (33)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics CA Cancer J Clin 55 2005 10 30
2. R. Tung-Ping Poon, S.T. Fan, and J. Wong Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma Ann Surg 232 2000 10 24 (Pubitemid 30456545)
3. S. Arii, Y. Yamaoka, and S. Futagawa Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan Hepatology 32 2000 1224 1229
4. J.A. McCubrey, L.S. Steelman, and S.L. Abrams Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279 (Pubitemid 44301348)
5. R.S. Sippel, and H. Chen Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation Surgery 132 2002 1035 1039 (Pubitemid 36026952)
6. H. Huynh, T.T. Nguyen, K.H. Chow, P.H. Tan, K.C. Soo, and E. Tran Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis BMC Gastroenterol 3 2003 19
7. T. Yoshida, T. Hisamoto, and J. Akiba Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors Oncogene 25 2006 6056 6066 (Pubitemid 44562404)
8. E.A. Rakha, D. Abd El Rehim, S.E. Pinder, S.A. Lewis, and I.O. Ellis E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance Histopathology 46 2005 685 693 (Pubitemid 40834828)
9. K.H. Lee, H.S. Min, and S.W. Han ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer Lung Cancer 60 2008 401 407 (Pubitemid 351726353)
10. G. Odabaei, D. Chatterjee, A.R. Jazirehi, L. Goodglick, K. Yeung, and B. Bonavida Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis Adv Cancer Res 91 2004 169 200 (Pubitemid 39140959)
11. M. Watatani, A.O. Perantoni, C.D. Reed, T. Enomoto, M.L. Wenk, and J.M. Rice Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl (acetoxymethyl) nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats Cancer Res 49 1989 1103 1109 (Pubitemid 19074820)
12. C. Challen, K. Guo, J.D. Collier, D. Cavanagh, and M.F. Bassendine Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas J Hepatol 14 1992 342 346
13. M. Tada, M. Omata, and M. Ohto Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing Cancer Res 50 1990 1121 1124 (Pubitemid 20083997)
14. P. Müller, C. Ostwald, and K. Püschel Low frequency of p53 and ras mutations in bile of patients with hepato-biliary disease: a prospective study in more than 100 patients Eur J Clin Invest 31 2001 240 247 (Pubitemid 32275731)
15. M. Leon, and M.C. Kew Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks Anticancer Res 15 1995 859 861
16. A.W. Tolcher, L. Reyno, and P.M. Venner A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer Clin Cancer Res 8 2002 2530 2535 (Pubitemid 34856336)
17. A.A. Adjei Ras signaling pathway proteins as therapeutic targets Curr Pharm Des 7 2001 1581 1594 (Pubitemid 32998572)
18. S.J. Moghaddam, E.N. Haghighi, and S. Samiee Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran World J Gastroenterol 13 2007 588 593 (Pubitemid 46210927)
19. V.L. Pannain, A.C. Bottino, R.T. Santos, H.S. Coelho, J. Ribeiro-Filho, and V.A. Alves Immunohistochemical detection of p21ras, c-myc and p53 oncoproteins in hepatocellular carcinoma and in non-neoplastic liver tissue Arq Gastroenterol 41 2004 225 228 (Pubitemid 40477212)
20. T. Takeuchi, K. Kagawa, and H. Hikita The expression of ras p21 product in hepatocellular carcinoma Nippon Shokakibyo Gakkai Zasshi 87 1990 1686 1691 (Pubitemid 20297206)
21. J.A. Radosevich, K.A. Gould, and G.K. Koukoulis Immunolocalization of ras oncogene p21 in human liver diseases Ultrastruct Pathol 17 1993 1 8 (Pubitemid 23044473)
22. D.T. Leicht, V. Balan, and A. Kaplun Raf kinases: function, regulation and role in human cancer Biochim Biophys Acta 1773 2007 1196 1212 (Pubitemid 47161035)
23. N. Kondoh, T. Wakatsuki, and A. Hada Genetic and epigenetic events in human hepatocarcinogenesis Int J Oncol 18 2001 1271 1278
24. Y.H. Hwang, J.Y. Choi, and S. Kim Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma Hepatol Res 29 2004 113 121 (Pubitemid 38667508)
25. F. McPhillips, P. Mullen, B.P. Monia, A.A. Ritchie, F.A. Dorr, and J.F. Smyth Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer Br J Cancer 85 2001 1753 1758 (Pubitemid 34081523)
26. R. Mukherjee, J.M. Bartlett, N.S. Krishna, M.A. Underwood, and J. Edwards Raf-1 expression may influence progression to androgen insensitive prostate cancer Prostate 64 2005 101 107 (Pubitemid 40734744)
27. Y. Tsuboi, T. Ichida, and S. Sugitani Overexpression of extracellular signal-regulated protein kinase (ERK) and its correlation with proliferation in human hepatocellular carcinoma Liver Int 24 2004 432 436 (Pubitemid 40484556)
28. V. Le Mellay, J. Troppmair, R. Benz, and U.R. Rapp Negative regulation of mitochondrial VDAC channels by C-Raf kinase BMC Cell Biol 3 2002 14
29. E. O'Neill, L. Rushworth, M. Baccarini, and W. Kolch Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1 Science 306 2004 2267 2270 (Pubitemid 40024466)
30. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
31. A. Alavi, J.D. Hood, R. Frausto, D.G. Stupack, and D.A. Cheresh Role of Raf in vascular protection from distinct apoptotic stimuli Science 301 2003 94 96 (Pubitemid 36801568)
32. S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol Cancer Ther 4 2005 677 685 (Pubitemid 40601850)
33. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34